FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics and medicine and concerns using ethyl ether of N-phenyl acetyl-L-prolylglycine for activating transcription factor HIF (hypoxia induced factor), as well as method of HIF activating using said factor and method of treating diseases, associated with HIF transcription factor deficiency.
EFFECT: group of inventions provides higher body resistance to oxygen supply deficit, which is effective for treatment of hypoxic states of various genesis.
3 cl, 1 tbl, 2 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF PLACENTAL INSUFFICIENCY IN SECOND HALF OF PREGNANCY IN SEROPOSITIVE BY CYTOMEGALOVIRUS WOMEN | 2020 |
|
RU2724395C1 |
| THERAPEUTIC AGENT FOR ENHANCING TISSUE OXYGENATION IN DIABETIC FOOT, AND A METHOD FOR USE THEREOF | 2017 |
|
RU2717674C1 |
| METHOD FOR PREDICTION OF DEVELOPING HAEMATOGENOUS METASTASES FOLLOWING COMBINED TREATMENT OF KIDNEY CANCER | 2013 |
|
RU2528100C1 |
| METHOD FOR DETERMINATION OF MISCARRIAGE THREAT FORMATION DURING THE FIRST TRIMESTER OF GESTATION IN CASE OF CYTOMEGALOVIRUS INFECTION IN EXACERBATION PERIOD OF HYPOXIA INDUCED FACTOR | 2016 |
|
RU2620565C1 |
| METHOD FOR EVEROLIMUS THERAPY EFFICIENCY PREDICTION FOR PATIENTS WITH METASTATIC RENAL CANCER | 2016 |
|
RU2616533C1 |
| METHOD FOR PREDICTION OF ATRIAL FIBRILLATION DEVELOPMENT IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME | 2022 |
|
RU2793677C1 |
| METHOD OF EVALUATING BIOACTIVITY OF CHEMICAL COMPOUNDS | 2013 |
|
RU2556823C2 |
| METHODS FOR INCREASING STABILISATION OF HYPOXYA INDUCED FACTOR-1 ALPHA | 2010 |
|
RU2521251C2 |
| NOOTROPIC COMPOSITION BASED ON POLYPEPTIDE COMPLEXES RECOVERED FROM NEURONAL PROGENITOR CELLS UNDER HYPOXIC CONDITIONS, AND A METHOD FOR PRODUCTION THEREOF | 2019 |
|
RU2732600C1 |
| METHOD FOR PREDICTION OF CLINICAL OUTCOME IN PATIENTS WITH METASTATIC KIDNEY CANCER | 2015 |
|
RU2589286C1 |
